Cilta-cel led to high response rates and a promising safety profile in a real-world population of patients with relapsed/refractory myeloma.

Belantamab mafodotin plus KRd had a a manageable safety profile and deep responses in pretreated multiple myeloma.

Older adults with acute myeloid leukemia treated with anthracyclines tended to live longer, but also had more time spent in the hospital compared with those treated with HMAs.

ODAC voted against the use of PD-L1 expression as a predictive biomarker in gastric cancers.

When it comes to cancer-related malnutrition, nurses should look out for more signs than just weight loss.

Panelists discuss how the current treatment landscape for chronic graft-versus-host disease includes a range of immunosuppressive approaches, from traditional corticosteroids and calcineurin inhibitors to newer approved agents like axatilimab, ruxolitinib, belumosudil, ibrutinib, and abatacept, emphasizing key considerations patients should be aware of when undergoing these therapies.

Panelists discuss how physician assistants educate and empower chronic graft-versus-host disease patients and their caregivers to recognize, report, and manage symptoms effectively, detailing strategies for patient communication, developing personalized symptom management plans, addressing challenging symptoms, and collaborating with the broader healthcare team to ensure comprehensive care.

Oncology nurses and APPs play a role in supporting caregivers while the patient they care for receives a diagnosis and cancer treatment.

Oncology nurses should inform patients about adverse events and the signs of interstitial lung disease before treating their breast cancer with T-DXd.

The agency approved selpercatinib for the treatment of patients with advanced or metastatic, RET-mutant medullary thyroid cancer.

Belantamab plus VRd led to promising outcomes in newly diagnosed transplant-eligible myeloma, study results showed.

An oncology research nurse balances patient care with rigorous data collection, emphasizing communication and collaboration to advance cancer research.

The FDA approved osimertinib for locally advanced, unresectable stage III EGFR-mutated non-small cell lung cancer.

Neoadjuvant immune checkpoint inhibitors plus chemotherapy also improved efficacy outcomes in PD-L1-positive/ERBB2-negative tumors.

Distant relapse-free survival was maintained with non-operative management of pMMR locally advanced rectal cancer.

Chlorhexidine dressings, along with proper patient education, are key in preventing central line-associated blood stream infections in patients with cancer.

A group of advanced practice providers discuss treatment options for a woman with newly diagnosed, transplant-ineligible multiple myeloma.

Olaparib after surgery resulted in durable response rates in patients with high-risk biochemically recurrent prostate cancer with BRCA2 alterations.

Belrestotug plus dostarlimab-gxly improved ORR in patients with previously untreated, unresectable, locally advanced or metastatic, PD-L1–high NSCLC.

Experts provide advice for patients and caregivers with relapsed/refractory multiple myeloma considering talquetamab or another bispecific, while all faculty will discuss unmet needs and future perspectives in the treatment of relapsed/refractory multiple myeloma.

Panelists discuss how the care team identifies and manages symptoms in chronic graft-versus-host disease patients, particularly those with advanced disease, emphasizing key symptoms to monitor, approaches to symptom identification, and the critical importance of early detection and management for improving patient outcomes.

Panelists discuss how chronic graft-versus-host disease typically progresses in patients requiring third-line treatment and beyond, focusing on severe symptoms, the impact on quality of life, and potential long-term consequences of inadequately managed symptoms.

Nurses play a crucial role for patients with prostate cancer undergoing radiation treatment, according to a radiation oncology nurse.

Patients with metastatic castration-resistant prostate cancer who received radium-223 prior to docetaxel had better quality of life and tolerability scores than those who received docetaxel first.